Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Joly

Showing results (331-340 of 336) with videos related to

Pageof 34
Sort By:
You have reached the last page of results.This site can display upto 336 results.
European Urology|October 4, 2014
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic ModelGwenaelle Gravis, Jean-Marie Boher, Karim Fizazi, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 7, 2025
Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical responseLucie Thorel, Enora Dolivet, Pierre-Marie Morice, et al.
International Journal of Cancer|July 19, 2019
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patientsEric Voog, Boris Campillo-Gimenez, Claude Elkouri, et al.
European Journal of Cancer (Oxford, England : 1990)|June 7, 2019
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancersChristine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
European Urology|October 28, 2017
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 TrialPernelle Lavaud, Gwenaëlle Gravis, Stéphanie Foulon, et al.
Bulletin Du Cancer|February 6, 2018
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]Christine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Pageof 34

Showing results (331-340 of 336) with videos related to

Sort By:
Pageof 34
You have reached the last page of results.This site can display upto 336 results.
European Urology|October 4, 2014
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic ModelGwenaelle Gravis, Jean-Marie Boher, Karim Fizazi, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 7, 2025
Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical responseLucie Thorel, Enora Dolivet, Pierre-Marie Morice, et al.
International Journal of Cancer|July 19, 2019
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patientsEric Voog, Boris Campillo-Gimenez, Claude Elkouri, et al.
European Journal of Cancer (Oxford, England : 1990)|June 7, 2019
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancersChristine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
European Urology|October 28, 2017
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 TrialPernelle Lavaud, Gwenaëlle Gravis, Stéphanie Foulon, et al.
Bulletin Du Cancer|February 6, 2018
[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]Christine Rousset-Jablonski, Fréderic Selle, Elodie Adda-Herzog, et al.
Pageof 34